Cargando…
A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949691/ https://www.ncbi.nlm.nih.gov/pubmed/35341943 http://dx.doi.org/10.1016/j.ctim.2022.102824 |
_version_ | 1784674965573861376 |
---|---|
author | Sankhe, Ajay Prabhakar Memane, Nanasaheb Somnath Gawali, Vijaykumar P. Memane, Sonal Nanasaheb Ramakrishnan, Ganesh Kundu, Tapanendu Bagul, Mayur Nimba Kumar, Ashotosh Bansal, Vikram Tiwari, Rashmi |
author_facet | Sankhe, Ajay Prabhakar Memane, Nanasaheb Somnath Gawali, Vijaykumar P. Memane, Sonal Nanasaheb Ramakrishnan, Ganesh Kundu, Tapanendu Bagul, Mayur Nimba Kumar, Ashotosh Bansal, Vikram Tiwari, Rashmi |
author_sort | Sankhe, Ajay Prabhakar |
collection | PubMed |
description | INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. METHODS: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. RESULTS: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. CONCLUSIONS: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone. |
format | Online Article Text |
id | pubmed-8949691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89496912022-03-25 A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India Sankhe, Ajay Prabhakar Memane, Nanasaheb Somnath Gawali, Vijaykumar P. Memane, Sonal Nanasaheb Ramakrishnan, Ganesh Kundu, Tapanendu Bagul, Mayur Nimba Kumar, Ashotosh Bansal, Vikram Tiwari, Rashmi Complement Ther Med Article INTRODUCTION: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. METHODS: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. RESULTS: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. CONCLUSIONS: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone. Published by Elsevier Ltd. 2022-08 2022-03-25 /pmc/articles/PMC8949691/ /pubmed/35341943 http://dx.doi.org/10.1016/j.ctim.2022.102824 Text en © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Sankhe, Ajay Prabhakar Memane, Nanasaheb Somnath Gawali, Vijaykumar P. Memane, Sonal Nanasaheb Ramakrishnan, Ganesh Kundu, Tapanendu Bagul, Mayur Nimba Kumar, Ashotosh Bansal, Vikram Tiwari, Rashmi A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title_full | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title_fullStr | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title_full_unstemmed | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title_short | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
title_sort | randomized, controlled, blinded, parallel group, clinical trial to study the role of ayurcov (ayurcoro3), one day regimen as an adjuvant therapy for covid-19 disease management, at dedicated covid hospital (dch) in india |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949691/ https://www.ncbi.nlm.nih.gov/pubmed/35341943 http://dx.doi.org/10.1016/j.ctim.2022.102824 |
work_keys_str_mv | AT sankheajayprabhakar arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT memanenanasahebsomnath arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT gawalivijaykumarp arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT memanesonalnanasaheb arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ramakrishnanganesh arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT kundutapanendu arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT bagulmayurnimba arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT kumarashotosh arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT bansalvikram arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT tiwarirashmi arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT sankheajayprabhakar randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT memanenanasahebsomnath randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT gawalivijaykumarp randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT memanesonalnanasaheb randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ramakrishnanganesh randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT kundutapanendu randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT bagulmayurnimba randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT kumarashotosh randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT bansalvikram randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT tiwarirashmi randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia |